A Study of Histopathological Features Associated with Papillary Thyroid Carcinoma
DOI:
https://doi.org/10.61841/zys2nr40Keywords:
Histopathological, Thyroid Carcinoma, Psammoma BodiesAbstract
Histopathological Papillary thyroid carcinoma diagnosis is based on the main criteria, which are mostly detected by the pathologist. Therefore, the aim of our study is to provide information focused on this criterion Features. The percentage of patients with cancer of thyroid gland for last three years (2017, 2018, and 2019) was and The histopathological section of the thyroid tissue that is affected by papillary thyroid carcinoma is the hypochromic nuclei, occurrence of ground glass, as the prominent pattern associated with papillae of the tumor, the true infiltration of the venous vessels and psammoma bodies, the cells of tumor infiltration surrounding the parenchyma, tumor cells containing enlarged, overlapping nuclei, high proliferation with irregular counters with enlargement, fine chromatin, thyroid carcinoma characterized by papillary architecture with fibrovascular cores and high proliferation cells characterized by a papillary growth pattern, where the stroma is represented by conjunctiva - vascular fine septa Intranuclear cytoplasmic inclusions with high proliferation cells Ground glass nuclei. Conclusions: the histopathological features of the papillary thyroid carcinoma depend on the shape of nuclei and psammoma bodies with high proliferation cells.
Downloads
References
[1] Ameer Ridha Dirwal, Karrar Jasim Hamzah, Hamed A. Hasan Aljabory and Qassim Abbas Mohammed
(2019) Histopathological study of features invaded by hepatocellular carcinoma in liver parenchyma.
Biochem. Cell. Arch. Vol. 19, No. 1, pp. 1925-1928, 2019
[2] Biersack, H.J., & Grünwald, F. (Eds.). (2005). Thyroid cancer. Springer Science & Business Media.
[3] Bogdanova, T.I., Zurnadzhy, L.Y., Nikiforov, Y.E., Leeman-Neill, R.J., Tronko, M.D., Chanock, S. &
Little, M.P. (2015). Histopathological features of papillary thyroid carcinomas detected during four
screening examinations of a Ukrainian-American cohort. British journal of cancer, 113(11), 1556-1564.
[4] Davies, L., Ouellette, M., Hunter, M., & Welch, H.G. (2010). The increasing incidence of small thyroid
Cancers: where are the cases coming from? The Laryngoscope, 120(12), 2446-2451.
[5] Ghossein, R.; Barletta, J.A.; Bullock, M.J.; Johnson, S.J.; Kakudo, K.; Lam, A.; Moonim, M.; Poller, D.N.;
Tallini, G.; Tuttle, R.M.; et al. (2019). Dataset for the reporting of thyroid carcinoma from the International
Collaboration on Cancer Reporting (ICCR). Available online: http://www.iccr-cancer.org/datasets/
datasetsunder-
[6] Haddad, R.I., Lydiatt, W.M., Bischoff, L., Busaidy, N.L., Byrd, D.R., Callender, G., & Haymart, M.
(2019). NCCN clinical practice guidelines in oncology (NCCN guidelines): thyroid carcinoma.
[7] Hamzah, K.J. & Hasso, S. A. (2019). Molecular prevalence of Anaplasma phagocytophilum in sheep from
Iraq. Open Veterinary Journal, 9(3), 238–245.
[8] Hasso, S.A. & Al-Janabi, K.J.H. (2019). Detection of Anaplasma phagocytophilum infection in sheep in
some provinces of Iraq. Al-Qadisiyah Journal of Veterinary Medicine Sciences, 18(1), 73-80.
[9] Haugen, B.R.M.; Alexander, E.K.; Bible, K.C.; Doherty, G.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.;
Randolph, G.; Sawka, A.; Schlumberger, M.; et al. (2016) American Thyroid Association Management
Guidelines for Adult Patients with Thyroid Nodules and Dierentiated Thyroid Cancer. Thyroid 2016, 26, 1–
133. [CrossRef] [PubMed]
[10] Iraqi Cancer Board (2015). Iraqi Cancer Registry 2008. Baghdad, Ministry of Health.
[11] Johannessen, J. V., & Sobrinho-Simoes, M. (1980). The origin and significance of thyroid psammoma
bodies. Laboratory investigation; a journal of technical methods and pathology, 43(3), 287-296.
[12] Kiyono, T., Katagiri, M., & Harada, T. (1994). The incidence of ground glass nuclei in thyroid diseases.
Thyroidology, 6(2), 43-481
[13] Kloos, R.T., Eng, C., Evans, D.B., Francis, G.L., Gagel, R.F., Gharib, H., & Wells Jr., S.A. (2009).
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19(6),
565-612.
[14] Luna, L.G. (1968). "Manual of Histologic Staining Methods of the armed force institute of Pathology." 3rd
Ed. McGraw-Hill, New York.
[15] NCDIR—National Centre for Disease Informatics and Research (2016). Trend over time for all sites and on
selected sites of cancer and projection of the burden of cancer. National Cancer Registry Programme. Indian
Council for Medical Research 3 Year Report of Population Based Cancer Registries. Ch. 10. National
Centre for Disease Informatics and Research; p. 89-125.
[16] Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D., & Giordano, T.
J. (2016). Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a
paradigm shift to reduce overtreatment of indolent tumors. JAMA oncology, 2(8), 1023-1029.
[17] Tatić, S. B. (2003). Histopathological and immunohistochemical features of thyroid carcinoma. Archive of
Oncology, 11(3), 173-174.
[18] Unnikrishnan AG, Menon UV (2011). Thyroid disorders in India: An epidemiological perspective. Indian J
Endocrinol Metab; 15: S78-81.
[19] Zablotska LB, Nadyrov EA, Rozhko AV, Gong Z, Polyanskaya ON, Mcconnell RJ, O’kane P, Brenner AV,
Little MP, Ostroumova E, Bouville A, Drozdovitch V, Minenko V, Demidchik Y, Nerovnya A,
Yauseyenka V, Savasteeva I, Nikonovich S, Mabuchi K, Hatch M (2015) Analysis of thyroid malignant
pathologic findings identified during 3 rounds of screening (1997-2008) of a cohort of children and
adolescents from Belarus exposed to radioiodines after the Chernobyl accident. Cancer 121(3): 457–466.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
